Skip to main content Accessibility help
×
Home
Hostname: page-component-cf9d5c678-9z9qw Total loading time: 0.656 Render date: 2021-08-01T21:32:24.847Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Prescribing antipsychotics for children and adolescents

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions[Opens in a new window]

Summary

The prescription of antipsychotic medication in children and adolescents (<18 years of age) has increased immensely for a wide range of disorders including psychoses, bipolar disorder, conduct disorder, pervasive developmental disorder and obsessive–compulsive disorder. This has led to some concerns particularly as the evidence base in some areas is not strong, and antipsychotic medication – both first generation (FGA) and second generation (SGA) – is associated with considerable side-effects. Evidence from an increasing number of randomised controlled trials (RCTs) points to therapeutic efficacy with moderate to large effect sizes. However, some RCTs have a small number of participants, are of short duration, and many are industry funded. The use of antipsychotics alongside psychosocial interventions can be recommended in certain disorders, provided there is continued, careful monitoring. It is important to note, however, that for many conditions the use of antipsychotics is not licensed in the UK.

Type
Articles
Copyright
Copyright © The Royal College of Psychiatrists, 2010 

There has been a huge increase in the prescription of antipsychotic medication to children and adolescents (<18 years of age).Footnote a However, there is a lack of empirical evidence to support an ever widening pattern of prescribing in this age group. In the USA, between 1999 and 2002 there was a sixfold increase in the prescription of antipsychotics to this population – 92% were second-generation antipsychotics (SGAs), and about a third (32%) were prescribed for mood disorders (Reference Olfson, Blanco and LiuOlfson 2006). Despite the lack of formal indications, one study revealed that 12% of all SGA prescriptions were for children under age 9 years (Reference Doey, Handelman and SeabrookDoey 2007), mostly for disruptive behavioural disorders.

This article assumes a thorough initial assessment of the patient, family and social circumstances. In only a few conditions such as psychosis is antipsychotic medication a first-line treatment. Antipsychotics, however, can be used in combination with other treatments such as cognitive–behavioural therapy (CBT), and always as part of a comprehensive treatment plan. Psycho-education about the disorder, the effects and side-effects of the medication is important, and may help with medication adherence.

An important issue is the licensing of SGAs in the UK. Risperidone and amisulpride are licensed for patients aged 15 or over, and clozapine for over-16s. A UK application for a licence for the use of risperidone for the management of severe aggression in autism was withdrawn by the drug company (Reference Morgan and TaylorMorgan 2007). With the adoption in 2007 of the European Union Regulation on Paediatric Medicines (Medicines and Healthcare products Regulatory Agency 2007), one hopes that clearer guidance will become available.

Schizophrenia

The evidence base demonstrating the efficacy of antipsychotic medication in the treatment of early-onset schizophrenia is relatively limited, but growing. A Cochrane review (Reference Kennedy, Kumar and DattaKennedy 2007) for childhood-onset schizophrenia (age at onset <13 years) found six studies (Table 1) with a total of 256 children and adolescents. The SGAs used were clozapine, risperidone and olanzapine. Although noting improvements with antipsychotic treatment, there was little to support the use of one antipsychotic over another, with the exception of clozapine over haloperidol. No superiority of SGAs over FGAs was found. A further systematic review and meta-analysis of 15 studies of antipsychotics in children and adolescents (up to the year 2003) showed a 55.7% average response to SGAs compared with 72.3% for FGAs. The effect size of 0.36 in favour of the FGAs was not significant (Reference Armenteros and DaviesArmenteros 2006). The review was limited by the methodological quality of the studies which included only two randomised controlled trials (RCTs) of FGAs – loxapine (Reference Pool, Bloom and MielkePool 1976) and haloperidol (Reference Spencer, Kafantaris and Padron-GayolSpencer 1992).

TABLE 1 Randomised controlled trials of antipsychotic medication for the treatment of schizophrenia

Study Participants Treatment Duration Effectiveness Adverse effects
Reference Faretra, Dooher and DowlingFaretra 1970 n = 60, 87% childhood-onset schizophrenia
Age 5–12 years
Fluphenazine: up to 1.25 mg three times a day, n = 30
Haloperidol: up to 1.25 mg three times a day, n = 30
8 weeks CGI: no differences fluphenazine v. haloperidol EPS, fluphenazine v. haloperidol
Relative risk 0.6 (95% CI 0.21–2.13)
Reference Engelhardt, Polizos and WaizerEngelhardt 1973 n = 30
Age 6–12 years
Fluphenazine: mean 10.4 mg/ day, n = 15
Haloperidol: mean 10.4 mg/ day, n = 15
12 weeks Clinical Global Improvement
CPRS: no differences fluphenazine v. haloperidol
EPS, fluphenazine v. haloperidol
Relative risk 2.0 (95% CI 0.5–2.46)
Reference Pool, Bloom and MielkePool 1976 n = 75
Mean age ∼15.5 years
Loxapine 87.5 mg/day
Haloperidol 9.8 mg/day
Placebo
4 weeks Both treatments significantly reduced BPRS total ratings compared with placebo
No significant differences observed between active treatment groups
EPS (e.g. muscle rigidity) noted in 19 (73%) of 26 receiving loxapine and 18 (72%) of 25 patients receiving haloperidol
Sedation also problematic
Reference Realmuto, Erickson and YellinRealmuto 1984 n = 21
Mean age ∼15.5 years
Thiothixene 16.2 mg
Thioridazine 178 mg
6 weeks Both treatments significantly reduced BPRS total scores Marked sedation
Reference Spencer, Kafantaris and Padron-GayolSpencer 1992 n = 16
Mean (s.d.) age: ∼8.9 years
Crossover design: haloperidol 1.8 mg/day v. placebo 6 weeks CGI–I much/very much improved: 12 (75%) patients of 16; marked reduction in severity of persecutory ideation and hallucinations Sedation
Reference Kumra, Frazier and JacobsenKumra 1996 n = 21
Mean (s.d.) age: 14.0 (2.3) years
Clozapine 176 (149) mg/day
Haloperidol 16 (8) mg/day
6 weeks Clozapine > haloperidol in terms of positive (SAPS total) and negative symptoms (SANS total) Clozapine: high rates of neutropenia and seizures
Reference Sikich, Hamer and BashfordSikich 2004 n = 50, broad psychotic disorders
Mean (s.d.) age: 14.7 (2.7) years
Risperidone 4 (1.2) mg/day
Olanzapine 12.3 (3.5) mg/day
Haloperidol 5.0 (2.0) mg/day
8 weeks BPRS–C reduction >20%: risperidone 74%, olanzapine 88%, haloperidol 54%
All CGI–I much/very much improved
EPS and weight gain more than reported in adult studies
Reference YaoYao 2003 n = 42 childhood- onset schizophrenia
Mean age ∼11 years
Risperidone 0.25–3 mg/day, n = 21
Haloperidol 0.5–12 mg/day, n = 21
6 weeks BPRS Risperidone fewer EPS than haloperidol
Relative risk 0.10 (95% CI 0.03–0.36, NNT = 2 (95% CI 2–3)
Reference XiongXiong 2004 n = 60
Age 7–16 years
Mean age ∼13 years
Length of illness 9–9.5 years
Risperidone 0.5–5 mg/day, n = 30
Chlorpromazine 50–400 mg/ day, n = 30
8 weeks BPRS: no improvement
No difference between risperidone and chlorpromazine
Restless
Relative risk 1.5 (95% CI 0.27–8.34)
Reference Shaw, Sporn and GogtayShaw 2006 n = 25
Mean age ∼12 years
Clozapine 327 (113) mg/day
Olanzapine 18.1 (4.3) mg/day
8 weeks Clozapine > olanzapine improvement in negative symptoms (SANS) Marked weight gain at 4 kg during the 8-week trial noted in both groups. At 2-year follow-up, 6 (40%) of 15 patients were observed to have dyslipidaemia
Reference Kumra, Kranzler and Gerbino-RosenKumra 2008 n = 39
Mean (s.d.) age: 15.6 (2.1) years
Clozapine 403.1 (201.8) mg/day
Olanzapine 26.2 (6.5) mg/day
12 weeks > 30% BPRS reduction: 66% clozapine, 33% olanzapine
Clozapine > ‘high-dose’ olanzapine negative symptoms (SANS)
CGI much/very much improved
Weight gain
High incidence of dyslipidaemia
Reference Kryzhanovskaya, Schulz and McDougleKryzhanovskaya 2009 n = 107
Mean (s.d.) age: 16.2 (1.3) years
Olanzapine 11.1 (4.0) mg/day v. placebo 6 weeks Olanzapine > placebo in terms of improvement from baseline to end-point on the BPRS–C (P = 0.003) and CGI–S (P = 0004) respectively
Treatment response rate was not significantly different between olanzapine (37.5%) and placebo (25.7%)
Mean weight gain 4.3 (3.3) kg with olanzapine
Reference Sanford and KeatingSanford 2007 n = 302
Mean age 15.5 years (range 13–17)
Aripiprazole 10 mg/day, aripiprazole 30 mg/day v. placebo 6 weeks Aripiprazole (10 mg and 30 mg doses) > placebo improvement from baseline to end-point on the PANSS Mild to moderate severity
Extrapyramidal disorder, somnolence, akathisia
Reference Haas, Eerdekens and KushnerHaas 2009b n = 257
Age 13–17 years
Risperidone low dose 0.15–1.6 mg/day (n = 132) v. high dose 1.5–6.0 mg/day (n = 125) risperidone 8 weeks PANSS total score improvement (mean (s.d.)) was significantly (P < 0.001) greater with high- (−23.6 (22.8)) v. low- dose (−12.5 (20.3)) risperidone All adverse events > with high dose, e.g. hypertonia 4.5% low dose v. 14.4% high dose
Reference Sikich, Frazier and McClellanSikich 2008 n = 119: schizophrenia 66%, schizoaffective 34% Olanzapine 2.5–20 mg/day, risperidone 0.5–6.0 mg/day or molindone 10–140 mg/day + benztropine 1 mg/day 8 weeks No significant differences in response rates: molindone 50%, olanzapine 34%, risperidone 46% Olanzapine significant weight gain and lipid changes

The recent US multicentre RCT, Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS; Reference Sikich, Frazier and McClellanSikich 2008), was designed to test whether SGAs are superior to FGAs in treating schizophrenia and schizoaffective disorder (Table 1). It was one of the largest studies involving 119 young people (aged 8–19 years). Results showed that risperidone and olanzapine (SGAs) were not superior to the FGA molindone. Given the side-effect profile of SGAs, particularly weight gain and metabolic problems, the authors questioned the current, almost exclusive, use of SGAs to treat early-onset schizophrenia and schizoaffective disorder. Indeed, given the similar findings of a lack of superiority of SGAs over FGAs in two large pragmatic trials for adults with schizophrenia (CATIE and CUtLAS; Reference Lewis and LiebermanLewis 2008), there are questions about the National Institute for Health and Clinical Excellence (NICE) guidelines (National Collaborating Centre for Mental Health 2002) recommending SGAs as first-line treatment.

Mixed dopamine agonists and antagonists

According to the dopamine hypothesis of schizophrenia, it is an excess of dopamine in the mesolimbic system which is responsible for increased salience being given to insignificant events and thoughts (Reference KapurKapur 2003), and which ultimately leads to the development of psychotic symptoms. Alongside this dopamine excess in the mesolimbic system there is a relative dopamine deficiency in the frontal lobes. The finding of a hypo- and hyperdopaminergic state has led to the development of mixed dopamine agonists and antagonists such as aripiprazole. Aripiprazole was designed to reduce dopamine overactivity in the mesolimbic system while purportedly increasing dopamine underactivity in frontal lobe projections. Preliminary evidence for its efficacy in adolescents comes from a short-term RCT (6 weeks) (Reference Sanford and KeatingSanford 2007) of aripiprazole v. placebo.

Cognition

Despite the claims of cognitive enhancement with SGAs, the evidence is weak. For example, methodological problems of earlier studies include the lack of a control group. Recent work suggests that some of the improvements in cognition in the first-episode schizophrenia group may have been due to practice effects (i.e. exposure, familiarity, and/or procedural learning) (Reference Goldberg, Goldman and BurdickGoldberg 2007). Differential medication effects on cognition appear small.

Clozapine

Various RCTs have shown clozapine to be more effective than haloperidol (Reference Kumra, Frazier and JacobsenKumra 1996), olanzapine (Reference Shaw, Sporn and GogtayShaw 2006) and high-dose olanzapine (Reference Kumra, Kranzler and Gerbino-RosenKumra 2008) (Box 1). Clozapine is effective against both positive and negative symptoms of schizophrenia. (Reference Kumra, Kranzler and Gerbino-RosenKumra 2008). Improvement with clozapine is seen within the first 6 weeks of treatment and is related to the plasma concentrations of n-desmethylclozapine (NDMC)/clozapine ratio (Reference Sporn, Vermani and GreensteinSporn 2007). Unfortunately, as with nearly all antipsychotics, the rate of side-effects in children and adolescents is higher than that typically found in the adult population. Interestingly, the side-effects do not appear to be related to clozapine dose, clozapine or NDMC plasma concentrations, or NDMC/clozapine ratio. Overall, clozapine appears to be a uniquely beneficial second-line agent for treating children with refractory schizophrenia (Reference Gogtay and RapoportGogtay 2008), and some argue for its early use in first-episode psychosis (Reference Agrid, Remington and KapurAgrid 2007).

BOX 1 First- and second-generation antipsychotics

  1. First-generation antipsychotics such as chlorpromazine, introduced in the 1950s, were thought to work by reducing dopamine overactivity in the mesolimbic pathways via blockade of D2 receptors

  2. Second-generation antipsychotics such as risperidone and olanzapine, introduced in the 1970s, were designed to be similar to clozapine, a superior antipsychotic, but with fewer side-effects. They have lower dopamine D2 receptor affinity and higher affinity for serotonergic 5-HT2A receptors

Pharmacokinetics

For clozapine and olanzapine, the pharmacokinetic profile varies greatly between individuals. The metabolism of olanzapine and clozapine is higher in males and in those who smoke (Reference Bigos, Pollock and ColeyBigos 2008). It is thought that aromatic polycarbons produced by smoking induce liver enzymes. The serum concentrations of olanzapine and olanzapine metabolites in adolescents show high intra-individual variability (1.04- to 10.7-fold, dose-corrected) (Reference Bachmann, Haberhausen and Heizel-GutenbrunnerBachmann 2008). For olanzapine, the daily dose, number of co-medications, body mass index and age all affect the variability of dose-corrected olanzapine serum concentrations (all P< 0.001). Monitoring of plasma levels is indicated, especially if there is doubt about the therapeutic response.

Bipolar disorder

There is an increasing trend to use antipsychotics in children and adolescents with bipolar disorder, both in the acute manic phase and as mood stabilisers (Reference Olfson, Blanco and LiuOlfson 2006), although the evidence base for this age group relies largely upon open trials and case reports. A small, double-blind, placebo-controlled study found that quetiapine in combination with divalproex was more effective for the treatment of adolescent bipolar mania than divalproex alone (Reference DelBello, Schwiers and RosenbergDelBello 2002), while separately, quetiapine appears to act faster than divalproex (Reference DelBello, Kowatch and AdlerDelBello 2006) (Table 2). A short-term (3 weeks) multicentre double-blind RCT involving out-patient and in-patient adolescents aged 13–17 years with an acute manic or mixed episode (Reference Tohen, Kryzhanovskaya and CarlsonTohen 2007) showed a significant benefit of olanzapine over placebo in reducing Young Mania Rating Scale scores (effect size 0.84). Risperidone also appears effective in the manic stage of the illness (Reference Haas, DelBello and PandinaHaas 2009a) (Table 2).

TABLE 2 Randomised controlled trials of antipsychotic medication for the treatment of bipolar disorder

Study Participants Treatment Duration Effectiveness Adverse effects
Reference DelBello, Schwiers and RosenbergDelBello 2002 n = 30, bipolar I disorder, mixed or manic
YMRS score >20
Mean age 14.3 years
Divalproex 20 mg/kg + quetiapine 450 mg/day or placebo 6 weeks More patients showed greater YMRS improvements with addition of quetiapine (87%) than placebo (53%) (P < 0.05) No EPS
Sedation: quetiapine 80% v. placebo 33%
Reference DelBello, Kowatch and AdlerDelBello 2006 n = 50, bipolar I disorder, manic, mixed Quetiapine 400–600 mg/ day v. divalproex 4 weeks No differences in YMRS improvement
Quetiapine faster onset of action
Sedation, dizziness and gastrointestinal upset 30–60%
Reference Tohen, Kryzhanovskaya and CarlsonTohen 2007 n = 160, 107 placebo
Mean age 15.1 years (s.d. = 1.3)
Olanzapine 2.5–20 mg/ day v. placebo 3 weeks The mean baseline to LOCF end-point change in the YMRS total olanzapine > placebo −7.65 v. −9.99, P < 0.001; effect size 0.84 Weight gain; rise in hepatic enzymes and prolactin in olanzapine group
Reference Haas, DelBello and PandinaHaas 2009a n = 169
Age 10–17 years
Risperidone low dose 0.5–2.5 mg/day (n = 50) v. high dose 3–6 mg/day (n = 61) v. placebo (n= 58) 3 weeks Mean (s.d.) improvement in YMRS total score was greater in both risperidone groups (0.5–2.5 mg: −18.5 (9.7); 3−6 mg: −16.5 (10.3)) v. placebo (−9.1 (11.0)) (P < 0.001) Somnolence: 19% placebo v. 42% low dose and 52% high dose

Expert guidelines on the treatment of paediatric bipolar disorder (Reference Kowatch, Fristad and BirmaherKowatch 2005) recommend the use of mood stabilisers or SGAs. A combination of mood stabilisers and SGAs is advocated in some cases. Indeed, polypharmacy has become more common. The choice of medication depends on the phase of the illness, presence of psychosis, presence of rapid cycling, risk of side-effects and, crucially, patient and family acceptance. Second-generation antipsychotics are recommended for treating psychotic symptoms but they also act as mood stabilisers. It is important to note that premature discontinuation of antipsychotic medication leads to a recurrence of psychotic symptoms in a large percentage of cases (Reference Kafantaris, Coletti and DickerKafantaris 2001).

According to expert consensus guidelines (Reference Kowatch, Fristad and BirmaherKowatch 2005), both clozapine and electro-convulsive therapy are considered treatments of last resort. It is suggested that clozapine be reserved for patients with bipolar disorder who have failed to respond adequately to at least two trials of a combination treatment regimen that includes at least two of the following: lithium, an anticonvulsant, and an antipsychotic.

Depression

According to the NICE guidelines (National Institute for Health and Clinical Excellence 2005), the treatment for mild cases of juvenile depression consists of brief psychosocial interventions followed by a trial of CBT and then antidepressant medication, if required. The ADAPT study (Reference Goodyer, Dubicka and WilkinsonGoodyer 2007), however, points to the earlier use of selective serotonin reuptake inhibitors (SSRIs) for moderate to severe depression, with little benefit seemingly conferred by the addition of CBT.

The effects of SGAs on serotonin (5-HT) receptors – as 5-HT2A and 5-HT2C antagonists, and as a partial 5-HT1A agonist in the case of aripiprazole – suggest that this class of drugs may be useful in treating depression. Available evidence from randomised placebo-controlled trials involving adults supports the partial effectiveness of olanzapine and quetiapine as augmenters of SSRIs in treatment-resistant depression (defined as a failure to respond to at least one adequate trial of an antidepressant) (Reference Shelton and PapakostasShelton 2008). For children and adolescents, however, such evidence is at present lacking.

Pervasive developmental disorder

It is generally held that there are no indications for the use of antipsychotics in treating the core symptoms of autism or pervasive developmental disorder. However, the Research on Pediatric Psychopharmacology Autism Network (Reference McDougle, Scahill and AmanMcDougle 2005) showed improvements in the areas of sensory motor behaviours, affectual reactions and sensory responses in children with autism given risperidone (Table 3). Small-scale RCTs point to a significantly greater reduction in sensory motor and language subscale scores on the Ritvo–Freeman Real Life Rating Scale with risperidone v. haloperidol (Reference Miral, Gencer and Inal-EmirogluMiral 2008), and an improvement in divided attention in young children with autism prescribed risperidone (Reference Troost, Lahuis and SteenhuisTroost 2005) (Table 3). However, the main indication for the use of antipsychotics appears to be to control temper tantrums, irritability, aggression and rapid mood changes. Six RCTs support the use of risperidone in reducing these behaviours (Reference Chavez, Chavez-Brown and SopkoChavez 2007). An RCT of olanzapine (Reference Hollander, Wasserman and SwansonHollander 2006) found an overall improvement on the Clinicians Global Impressions–Improvement (CGI–I) scale, but no changes in aggression or irritability. There is less evidence supporting the use of other SGAs such as ziprasidone and aripiprazole (Reference Chavez, Chavez-Brown and SopkoChavez 2007). A small RCT by Reference Luby, Mrakotsky and StaletsLuby et al (2006) pointed to the relative safety of risperidone in the pre-school population (children under 5 years old), which is important as this is an age group likely to be targeted for this developmental disorder.

TABLE 3 Randomised controlled trials of antipsychotic medication for the treatment of pervasive developmental disorder and Tourette syndrome/tics

Study Participants Treatment Duration Effectiveness Adverse effects
Pervasive developmental disorder
Reference McCracken, McGough and ShahMcCracken 2002 n = 101 with autism
Mean age 9.2 years
Age range 5–17 years
Risperidone 1.8 (0.7) mg/day (n = 49) v. placebo (n = 52) 8 weeks Mean (s.d.) ABC–I score: 56.9% decrease with risperidone (from 26.2 (7.9) at baseline to 11.3 (7.4) at 8 weeks v. 14.1% decrease with placebo (from 25.5 (6.6) to 21.9 (9.5)) (P < 0.001)
Effect size −1.2
Tiredness during the day (P < 0.0001), excessive appetite (P < 0.0001), difficulty waking (P < 0.05), excessive saliva or drooling (P = 0.04), and dizziness or loss of balance (P = 0.04), increased appetite (73%), fatigue (59%), drowsiness (49%). Weight gain 2.7 kg risperidone v. 0.8 kg placebo
Reference Shea, Turgay and CarrollShea 2004 n = 79: PDD n = 41, controls n =39
Mean age 7.5 years
Risperidone 1.17 (0.7) mg/day 8 weeks Mean ABC–I score: with risperidone decrease from 18.9 at baseline to 6.8 at end-point; placebo 21.2 to 14.7 (P < 0.001)
Effect size −0.8
Somnolence: 72.5% risperidone v. 7.7% placebo
Mean weight gain 2.7 kg v. 1.0 kg EPS: tremor, hypokinesia, increased systolic blood pressure, tachycardia
Reference Nagaraj, Singhi and MalhiNagaraj 2006 n = 39 with autism
Age range 2–9 years
Risperidone 0.5 mg/ day for 2 weeks then 1 mg/day 6 months > 20% improvement on the CARS: risperidone 12/19 v. placebo 0/20, P < 0.001 Sedation
Reference Troost, Lahuis and SteenhuisTroost 2005 n = 24 with PDD
Age range 5–17 years
Risperidone discontinuation 8 weeks 8/12 risperidone relapsed v. 3/12 placebo, P = 0.04 Weight gain of 5.7 kg with risperidone
Reference Hollander, Wasserman and SwansonHollander 2006 n = 11 with PPD
Age 6–14 years
Olanzapine mean (s.d.) dose: 10 (2) mg/day 8 weeks CGI–I: 50% on olanzapine v. 20% on placebo were responders Weight gain 3.3 kg on olanzapine v. 0.9 kg placebo
Reference Luby, Mrakotsky and StaletsLuby 2006 n = 23 with ASD
Age 2.5–6 years
Risperidone 0.5–1.5 mg/day (n = 11) v. placebo (n= 12) 6 months No significant differences in autism severity scores Weight gain and hyperprolactinaemia
Reference Miral, Gencer and Inal-EmirogluMiral 2008 n = 28 with autism
Age 7–17 years
Risperidone mean (s.d.) dose: 2.6 (1.3) mg/day (n = 13)
Haloperidol 2.6 (0.8) mg/day (n = 15)
10 weeks Reduction from baseline in Ritvo–Freeman Real Life Rating Scale, sensory motor (subscale I) and language (subscale V) scores, risperidone > haloperidol (P < 0.05) ABC and Turgay DSM–IV PDD reduction in scale scores, risperidone > haloperidol (P < 0.05 and P < 0.01 respectively) Few EPS
Tourette syndrome/tics
Reference Sallee, Nesbitt and JacksonSallee 1997 n = 22
Age 7–16 years
Pimozide 3.4 (1.6) mg/day v. haloperidol 3.5 (2.2) mg/day v. placebo 24 weeks crossover trial Pimozide > placebo P = 0.05
Tourette syndrome/tic subscale score 26
Effect size 0.5
Haloperidol v. placebo: P not significant
Effect size 0.3
41% of those on haloperidol experienced side-effects, mainly EPS
Reference Sallee, Kurlan and GoetzSallee 2000 n = 28
Mean age 11.5 years
Ziprasidone 28.2 mg/day (n = 16) v. placebo (n = 12) 8 weeks Tic severity: −39% ziprasidone v. −16% placebo (P = 0.02)
Effect size −0.8
Weight gain 0.7 kg ziprasidone v. 0.8 kg placebo
Reference Gaffney, Perry and LundGaffney 2002 n=21 Risperidone 1.5 mg/ day (n = 9)
Clonidine 0.18 mg/ day (n = 12)
8 weeks Response similar in both groups
Tics reduced: 21% risperidone v. 26% clonidine
Weight gain: 2.1 kg risperidone v. 0.1 kg clonidine
Sedation: clonidine > risperidone
Reference Scahill, Leckman and SchultzScahill 2003 n = 26
Mean age 11.1 years
Risperidone 2.5 mg/ day (n = 12) v. placebo (n = 14) 8 weeks Tic severity reduced: 36% risperidone v. 9% placebo (P < 0.01); effect size 1.0 No EPS
Weight gain: 2.8 kg risperidone v. 0 kg placebo
Reference Gilbert, Batterson and SethuramanGilbert 2004 n = 9
Mean age 11 years
Crossover: risperidone 2.5 mg/ day and pimozide 2.4 mg/day 4 weeks Greater reduction in tic severity with risperidone (42%) v. pimozide (21%), P = 0.05 Weight gain: 1.9 kg risperidone v. 1.0 kg pimozide

Conduct disorder

Conduct disorder is often associated with psychosocial stressors and adversity. Environmental, social and psychological interventions are therefore the first line of treatment. Treatment of comorbid conditions such as attention-deficit hyperactivity disorder, which may require medication, is important; however, antipsychotic medication for ‘pure’ conduct disorder is not often used in routine clinical practice in the UK.

For children admitted to hospital with severe aggression and conduct disorder, both lithium and haloperidol (dose 1–6 mg/day) reduce aggression (Reference Campbell, Small and GreenCampbell 1984); however, there are notable side-effects with both drugs. Double-blind controlled studies show that risperidone is effective in reducing symptoms (Table 4), with effect sizes ranging from 0.6 (medium) to 1.5 (very large) (Reference Jensen, Buitelaar and PandinaJensen 2007). However, the RCTs share methodological problems of small trial numbers, high drop-out rates, and selection issues, with most children having low IQs. Nevertheless, when an improvement occurs, it does so in the first 2 weeks of treatment. An important question is the length of treatment, as withdrawal may lead to a recurrence of symptoms. Long-term maintenance therapy with risperidone appears effective, with few reported adverse effects (Reference Jensen, Buitelaar and PandinaJensen 2007).

TABLE 4 Randomised controlled trials of antipsychotic medication for the treatment of disruptive behaviour disorders

Study Participants Treatment Duration Effectiveness Adverse effects
Reference Findling, McNamara and BranickyFindling 2000 n = 20: conduct disorder n = 10, controls n = 10
Mean 9.2 years
Risperidone 0.03 mg/kg 10 weeks RAAPP score: −1.7 risperidone v. −0.2 placebo (P < 0.05)
CGI: −2.6 risperidone v. −0.1 placebo (P < 0.01)
Effect size −1.0
No EPS
Weight gain: 4.2 kg
risperidone v. 0.7 kg placebo (P < 0.01)
Reference Buitelaar and van der GaagBuitelaar 2001 n = 38: DBD/ADHD n = 19, controls n =19
Mean age 14 years
IQ 60–90
Risperidone 2.9 (0.04) mg/day v. placebo 6 weeks CGI score: −1.6 risperidone v. +0.2 placebo (P < 0.001)
Effect size −1.5
ABC significantly improved with risperidone (P < 0.05)
Risperidone: no or mild EPS
Weight gain: 2.3 kg risperidone v. 0.6 kg placebo (P < 0.05)
Van Bellinghen 2001 n = 14: DBD n = 7, controls n = 7
Age 6–14 years
IQ 45–85
Risperidone 1.2 (0.05) mg/day v. placebo 4 weeks ABC score improvement in 65% risperidone v. 7% placebo EPS similar with risperidone and placebo
Weight gain: 1.8 kg risperidone v. 0.6 kg placebo (P = 0.319)
Reference Snyder, Turgay and AmanSnyder 2002 n = 110: DBD n = 53, controls n= 57
Mean age 8.7 years IQ 36–84
Risperidone 0.98 (0.03) mg/day v.placebo 6 weeks N–CBRF conduct scale score: −15.8 risperidone v. – 6.8 placebo (P < 0.001)
Effect size – 0.6
Hypertonia: 8% risperidone v. 2% placebo
Somnolence: 42% v. 14%
Weight gain: 2.2 kg v. 0.2 kg
Reference Aman, De Smedt and DerivanAman 2002 n = 118: DBD n = 55, controls n= 63
Age 5– 2 years
IQ 36–84
Risperidone 1.2 (0.04) mg/day v. placebo 6 weeks N–CBRF conduct scale score: −15.2 risperidone v. −6.2 placebo (P < 0.01)
Effect size – 0.8
BPI aggressive scale: −6.8 risperidone v. −2.4 placebo (P < 0.01)
Low EPS: risperidone = placebo
Weight gain: 15% (2.2 kg) v. 2% (0.9 kg)
Reference Hollander, Wasserman and SwansonHollander 2006 n = 11
Age 6–14 years
Olanzapine mean (s.d.) dose: 10 (2) mg/day 8 weeks CGI–I: 50% on olanzapine v. 20% on placebo were responders Weight gain: 3.3 kg on olanzapine v. 0.9 kg placebo
Reference Reyes, Buitelaar and TorenReyes 2006 n = 335: DBD n = 172, controls n =163
Mean age 11 years IQ =55
Risperidone 0.02 mg/kg v. placebo 6 months DBD with N–CBRF conduct scale scores
Symptom recurrence rate: 42.3% placebo v. 27.3% risperidone
Hazard ratio 2.24 (95% CI 1.54–3.28)
Weight gain (3.2 kg) and somnolence (11.6%) with risperidone
Infrequent EPS and prolactin- related adverse events

There are no NICE guidelines for pharmacological treatments of conduct disorder; instead, parent training is advocated (National Institute for Health and Clinical Excellence 2006). Overall, with children and adolescents medication should be reserved for those whom psychosocial treatments have failed or for whom they have proved inadequate. For severe aggression, a trial of medication may then be appropriate.

Tourette syndrome and tics

As a treatment rationale for Tourette syndrome and tics, antipsychotics are thought to act primarily by blocking dopamine receptors, thus decreasing dopaminergic input from the substantia nigra and ventral tegmentum to the basal ganglia. Pimozide and haloperidol are effective (Reference Sallee, Nesbitt and JacksonSallee 1997); however, both have serious side-effects – haloperidol producing extrapyramidal symptoms, and pimozide prolonging the QT interval with associated risk of a fatal ventricular arrhythmia. Randomised controlled trials have shown risperidone to be superior to placebo (Reference Scahill, Leckman and SchultzScahill 2003), equally effective as clonidine – an alpha adrenergic agonist (Reference Gaffney, Perry and LundGaffney 2002) – and superior to pimozide (Reference Gilbert, Batterson and SethuramanGilbert 2004). Doses ranging from 1.0 to 2.5 mg/day are effective and neurological side-effects rare. Ziprasidone is also effective (Reference Sallee, Kurlan and GoetzSallee 2000), although cardiac side-effects with QT prolongation are concerning. These trials are limited by small numbers and short duration (Table 3).

Obsessive–compulsive disorder

The Pediatric OCD Treatment Study (POTS) Team (2004) found CBT to be an important component of treatment; however, further improvement was gained with the addition of an SSRI, sertraline. A recent review and meta-analysis (Reference Watson and ReesWatson 2008) demonstrated positive effects for CBT and medication in treating obsessive–compulsive disorder (OCD); however, there are no reported RCTs of antipsychotic augmentation with SSRIs in children and adolescents. A meta-analysis of nine studies of adults with treatment-resistant OCD (Reference Bloch, Landeros-Weisenberger and KelmendiBloch 2006) showed a significant absolute risk difference (ARD) of 0.22 (95% CI 0.13–0.31) in favour of antipsychotic augmentation; those with comorbid tics had a particularly beneficial response (ARD = 0.43, 95% CI 0.19–0.68).

Anorexia nervosa

Psychological interventions are the mainstay of treatment for eating disorders, and according to the NICE guidelines (National Collaborating Centre for Mental Health 2004) medication is not advocated for anorexia in any age group. There is some evidence for the use of olanzapine in adults with anorexia nervosa, but only 16 case reports have been published on its use in children and adolescents (Reference Mehler-Wex, Romanos and KirhheimerMehler-Wex 2008). The results of an RCT in adolescent females are awaited (Reference Spettigue, Buchholz and HendersonSpettigue 2008). Case reports reveal positive psychopathological effects and good tolerability of quetiapine in children and adolescents with severe anorexia (Reference Mehler-Wex, Romanos and KirhheimerMehler-Wex 2008). In a small subset of patients with severe treatment-resistant anorexia, extreme weight phobia, delusional body image disturbances or severe hyperactivity, a trial of an SGA may be justified. Clearly, controlled studies are needed.

Antipsychotics and pre-school children

There is a growing literature, mainly from the USA, on the use of SGAs in the very young (under 5 years of age) for the treatment of bipolar disorder and aggression in autism. There is only limited evidence for such usage and the side-effect profile is even greater in this age group (Reference Gleason, Egger and EmslieGleason 2007). If a decision is made to use this medication, it should be prescribed very cautiously and with careful monitoring alongside psychosocial interventions (see guidelines, Reference Gleason, Egger and EmslieGleason 2007). Such practice is not licensed in the UK and is not recommended.

Side-effects

The side-effect profile of antipsychotics differs according to their receptor blockade potential (Reference Correll and CarlsonCorrell 2006, Reference Correll2008). There are important differences between SGAs and FGAs in terms of weight gain and metabolic syndrome, with perhaps more similarities than originally thought with respect to extrapyramidal side-effects and hyperprolactinaemia. The major side-effects (Table 5) are discussed below.

TABLE 5 Side-effect profile of second-generation antipsychotics and haloperidol (first-generation antipsychotic)a

Adverse effect Aripiprazole Clozapine Olanzapine Quetiapine Risperidone Ziprasidone Haloperidol
Anticholinergic 0 +++ + 0/+ 0 0 +
Parkinsonian 0/+ 0 + 0 ++ + +++
Akathisia ++ + + + + + +++
Diabetes 0/+ +++ +++ ++ + 0/+ 0/+
Raised lipids 0/+ ++ +++ + + 0/+ 0/+
Weight gain 0/+ +++ +++ ++ + + +
Neutropenia 0/+ +++ 0/+ 0/+ 0/+ 0/+ 0/+
Orthostasis 0 +++ + ++ + 0 0
Raised prolactin 0 0 0 0 +++ 0/+ +++
Lowered prolactin ++ 0 0 0 0 0 0
Increased QTc 0 0/+ 0 + 0 ++ +++
Sedation 0 +++ ++ ++ 0/+ 0/+ +
Seizure 0/+ ++ 0/+ 0/+ 0/+ 0/+ 0/+
Tardive dyskinesia 0 0 0/+ 0/+ 0/+ 0/+ +
Withdrawal dyskinesia 0/+ 0 0/+ 0/+ + + +

Weight gain

Weight gain with SGAs is greater in children and adolescents than in adults (Reference Correll and CarlsonCorrell 2006). Excessive weight gain is associated with significant medical morbidity and mortality, including dyslipidaemia, diabetes mellitus, polycystic ovary syndrome, hypertension and sleep apnoea. The potential for weight gain, both in terms of the proportion of patients affected and amount of weight gained, is greatest with olanzapine and lower with quetiapine (Reference Correll and CarlsonCorrell 2006). Weight gain is also low with aripiprazole (Reference Findling, Kauffman and SalleeFindling et al, 2008) and ziprasidone.

There is some evidence from a recent meta-analysis that non-pharmacological interventions are effective in reducing weight gain in those prescribed antipsychotics (Reference Álvarez-Jiménez, Hetrick and González-BlanchÁlvarez-Jiménez 2008). A Cochrane review on the usefulness of switching antipsychotics is awaited (protocol: Reference Mukundan, Faulkner and CohnMukundan 2007). Two RCTs (Reference Klein, Cottingham and SorterKlein 2006; Reference Wu, Zhao and GuoWu 2008), one in adolescents, point to the benefit of metformin as an adjunctive treatment. This is a cheap, easily administered drug and, apart from a risk of lactic acidosis in renal failure and chronic alcoholism, a safe treatment. Metformin leads to stabilisation of weight.

Metabolic syndrome

As a potential result of significant weight gain, SGAs have been associated with lipid abnormalities such as elevated triglyceride, total cholesterol and low-density lipoprotein (LDL) cholesterol levels, and/or decreased high-density lipoprotein (HDL) cholesterol levels in children and adolescents (Reference CorrellCorrell 2008). It is not clear how frequently metabolic syndrome – dyslipidaemia, glucose intolerance, hypertension and abdominal obesity – occurs in children and adolescents. The syndrome appears to result from insulin resistance secondary to weight gain.

The US Food and Drug Administration (FDA) has issued a ‘black box’ warning concerning the development of diabetes mellitus in patients receiving any SGAs. There have been case reports of new-onset diabetes in antipsychotic-treated children and adolescents. In an epidemiological study in New Zealand, the estimated incidence of diabetes mellitus was 4 cases per 1000 patient-years of treatment (95% CI 0.5–15) (Reference Harrison-Woolrych, Garcia-Quiroga and AshtonHarrison-Woolrych 2007). Risk factors for the development of diabetes include obesity, rapid weight gain, family history of diabetes and hyperlipidaemia (Reference CorrellCorrell 2008).

Hyperprolactinaemia

Secretion of prolactin from the pituitary is regulated by tonic dopaminergic inhibition. Consequently, the majority of FGAs and SGAs elevate prolactin levels. Hyperprolactinaemia can result in several side-effects: amenorrhoea and oligomenorrhoea, erectile dysfunction, decreased libido, hirsutism, and breast symptoms including galactorrhoea. Prolactin levels are not closely correlated with these symptoms. Hyperprolactinaemia appears dose dependent, tends to normalise over time, and resolves after antipsychotic discontinuation (Reference Findling, Kusumakar and DanemanFindling 2003). The relative potency of antipsychotic drugs to induce hyperprolactinaemia is greatest with risperidone and least with aripiprazole. If the patient develops persistently high prolactin levels, switching to a medication with a lower risk is often helpful. Aripiprazole may actually lower prolactin levels.

Extrapyramidal side-effects

Children and adolescents appear more sensitive than adults to extrapyramidal side-effects such as Parkinsonian side-effects and dystonia (Reference CorrellCorrell 2008). Although one study showed that the extrapyramidal side-effect rate was similar between FGAs and SGAs (Reference Sikich, Hamer and BashfordSikich 2004), the severity of extrapyramidal symptoms was greater with haloperidol. A review of extrapyramidal side-effects with risperidone in paediatric patients indicates a rate ranging from 8 to 26% (Reference CorrellCorrell 2008). Clozapine (Reference Kumra, Frazier and JacobsenKumra 1996; Reference Shaw, Sporn and GogtayShaw 2006) and quetiapine (Reference DelBello, Schwiers and RosenbergDelBello 2002) appear to be associated with relatively low rates, as is the case in adults. Dose reduction or switching medication are the first lines of treatment, although oral or intramuscular anticholinergic medications can also be used.

Neurological adverse events

Fits

Children and adolescents taking clozapine may be at higher risk than adults for developing seizures or epileptiform discharges on an electroencephalogram (EEG) (Reference Findling, Steiner and WellerFindling 2005). A pre-treatment EEG may be useful, and a repeat EEG when clinically indicated (i.e. overt or impending seizure activity, a daily dose of 600 mg or blood level >600 ng/ml). Prophylactic treatment with an anticonvulsant (non-myelosuppressive) is sometimes necessary.

Sedation and somnolence

Sedation and somnolence are frequent side-effects that are usually dose dependent. Sedation rates range from 0 to 33% for aripiprazole, and between 25 and 90% for risperidone, olanzapine and clozapine (Reference CorrellCorrell 2008). Somnolence appears to reduce with time due to developing tolerance.

Neutropenia and agranulocytosis

There is a risk of neutropenia and agranulocytosis with clozapine treatment, so regular monitoring is required. In a chart review of clozapine-treated paediatric in-patients (Reference Gerbino-Rosen, Roofeh and TompkinsGerbino-Rosen 2005), the cumulative 1-year probability of an initial adverse haematological event was 16.1% (neutropenia, 13%; agranulocytosis, 0.6%). However, 45% of the children and adolescents with newly emerging neutropenia were successfully re-challenged (under the supervision of a haematologist), and only 5% of patients discontinued clozapine because of agranulocytosis (n = 1) or neutropenia (n = 7). The adjunctive use of lithium to reduce neutropenia has been suggested (Reference Sporn, Gogtay and Ortiz-AguavoSporn 2003), but it is not supported by all haematologists. Over time, the bone marrow seems to adjust and treatment can continue (Reference Findling, Frazier and Gerbino-RosenFindling 2007). In general, specific monitoring is not required for other antipsychotics, except in patients with low baseline white blood cell counts.

Cardiac effects

Myocarditis and cardiomyopathy

Clozapine has been associated with a small risk for myocarditis, which occurs early on in treatment. A baseline electrocardiogram (ECG) is necessary. Blood pressure and pulse checks are initially performed daily to detect orthostatic changes and tachycardia. Some cardiomyopathies may be induced by tachycardia, and they can be avoided by early detection and appropriate dose adjustments and/or addition of a beta-blocker. Clozapine should be discontinued if either myocarditis or cardiomyopathy develops.

QTc prolongation

QTc prolongation (>430 ms) has been described in children and adolescents treated with ziprasidone (mean QTc prolongation 28 ms, s.d. = 26), which is unrelated to the dose of the drug (Reference Blair, Scahill and StateBlair 2005). Prolonged QTc is associated with a risk of cardiac arrest and sudden death (Reference Hobbs, Peterson and MossHobbs 2006).

Assessment and monitoring

The following tests and measurements are recommended at baseline and at regular 3–6 monthly follow-up intervals: weight, blood pressure, blood tests (full blood count at baseline only, except with clozapine, for which more regular monitoring is required), liver function tests, fasting lipids, cholesterol, blood sugar and prolactin (Reference CorrellCorrell 2008). Glucose, triglyceride and LDL cholesterol levels are strongly affected by eating, therefore fasting blood values should be used. Unfortunately, fasting glucose is a highly insensitive marker because the body compensates by increasing insulin levels before hyperglycaemia develops (Reference CorrellCorrell 2008). Ideally, measurement of insulin should be available. Haemoglobin A1c is an insensitive screening test, and therefore should only be used for monitoring in patients with diabetes. Prolactin levels should be measured while fasting in the morning, as prolactin levels vary during the day and can be elevated by food, exercise, stress, as well as medications (Reference CorrellCorrell 2008).

Conclusions

Fortunately, the evidence base for the use of antipsychotics in children and adolescents has increased with a number of RCTs now available. The quality of RCTs is variable, with problems of short duration, unclear allocation, selection bias and participant drop out. Many studies are funded by the pharmaceutical industry. In the majority, however, the statistical analyses with stated primary outcome measures and intention-to-treat analyses are an improvement. The evidence is reasonably strong for antipsychotics being effective in a number of disorders such as psychosis, pervasive developmental disorder, conduct disorder and bipolar disorder; however, the side-effect profile is concerning and requires continuous monitoring.

Advantages and disadvantages

There do not appear to be advantages of SGAs over FGAs in treating psychosis (Reference Armenteros and DaviesArmenteros 2006; Reference Kennedy, Kumar and DattaKennedy 2007; Reference Sikich, Frazier and McClellanSikich 2008). Indeed, the weight gain and metabolic problems associated with SGAs raise important public health concerns given the widespread use of these medications (Reference Sikich, Frazier and McClellanSikich 2008). Caution is further heightened by the finding that, generally, side-effects in children and adolescents appear more severe than in adults (Reference CorrellCorrell 2008). The lower rate of tardive dyskinesia with SGAs (Corell 2007) is potentially an argument in favour of SGAs over FGAs. With the notable exception of clozapine, there is no evidence for greater efficacy of one antipsychotic over another in the treatment of psychosis in this age group, although a recent meta-analysis (Reference Leucht, Komossa and Rummel-KlugeLeucht 2009) for adult studies showed some superiority of olanzapine over aripiprazole, quetiapine, risperidone and ziprasidone. Choice may therefore be guided by the side-effect profile and the knowledge that the switching of antipsychotics is not backed by evidence (but see review by Reference Buckley and CorrellBuckley 2008).

Using higher than British National Formulary doses of antipsychotics does not appear effective (only indirect evidence for high-dose olanzapine is available: Reference Kumra, Kranzler and Gerbino-RosenKumra 2008) and such practice is not recommended. Indeed, a low-dose strategy is the norm in early-intervention psychosis practice. This is in line with findings from imaging studies which show a therapeutic antipsychotic response is achieved with 70% D2-receptor blockade (Reference Kapur, Zipursky and JonesKapur 2000). Importantly, dosing should be more conservative for untreated new-onset patients than for those with multiple episodes (Reference Berger, Proffitt and McConchieBerger 2008).

Indications for treatment

The increasing prescription of antipsychotics in children and adolescents needs to be examined critically. Although there are recognised indications, there is a danger that these medications will be used as first-line treatments, particularly if psychological treatments are not readily available, as for example in the case of conduct disorder (Reference Doey, Handelman and SeabrookDoey 2007). This would be unfortunate and a potentially serious error given the side-effect profile of antipsychotics. Several measures might help: adoption of protocols which include reference to NICE guidelines; education for service users and parents; audit of clinicians' prescribing habits; and making psychological treatments more available and easier to implement. This does raise the question, however, of the relative effectiveness and indications for psychological and drug treatments. Unfortunately, information to help rational prescribing is not readily available. Indeed, there is a pressing need for RCTs of medication, psychological treatments and their combination. Such trials have already been very informative in cases of treating adolescent depression (Reference March, Silva and PetryckiMarch 2004; Reference Goodyer, Dubicka and WilkinsonGoodyer 2007).

Current recommendations

The current recommendation is that antipsychotics should only be used as part of a comprehensive treatment plan, which involves psychoeducation and consideration of appropriate psychological and psychosocial interventions. Practising clinicians should be aware of the limited licensing for these medications. Clearly, further guidance backed by evidence is essential.

MCQs

  1. 1 The prescription of antipsychotics in children and adolescents in the USA has:

    1. a remained fairly static since 1999

    2. b decreased alongside the use of psychosocial treatments

    3. c increased only marginally

    4. d increased over sixfold between 1999 and 2002

    5. e reduced dramatically following FDA warnings.

  2. 2 Weight gain as a side-effect of antipsychotic medication:

    1. a is more frequent in children and adolescents

    2. b is more frequent with FGAs

    3. c is of only marginal significance

    4. d occurs equally with all SGAs

    5. e is more frequent in adults.

  3. 3 Raised prolactin levels:

    1. a are seen with all SGAs

    2. b are due to a peripheral effect of antipsychotics

    3. c continue to rise with continued use of antipsychotic medication

    4. d are irreversible

    5. e can lead to sexual side-effects.

  4. 4 Clozapine:

    1. a is not recommended for children and adolescents under 18 years

    2. b is more effective that other antipsychotics in children and adolescents

    3. c is not associated with serious side-effects in children and adolescents

    4. d is recommended as a first-line treatment for schizophrenia

    5. e unlike other antipsychotics is not associated with weight gain.

  5. 5 For children and adolescents with autism, antipsychotic medication:

    1. a is recommended routinely to treat core deficits

    2. b is not associated with adverse side-effects

    3. c has been shown to reduce irritability

    4. d should be used without other psychosocial interventions

    5. e is not used owing to the lack of research evidence.

MCQ answers

1 2 3 4 5
a f a t a f a f a f
b f b f b f b t b f
c f c f c f c f c t
d t d f d f d f d f
e f e f e t e f e f

Footnotes

Declaration of Interest

A.C.J. has received sponsorship from UCB Pharma.

a Clinicians should be aware of the limited licensing of different antipsychotics for children and adolescents.

References

Agrid, O, Remington, G, Kapur, S et al (2007) Early use of clozapine for poorly responding first-episode psychosis. Journal of Clinical Psychopharmacology; 27: 369–73.Google Scholar
Álvarez-Jiménez, M, Hetrick, SE, González-Blanch, C et al (2008) Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry; 193: 101–7.CrossRefGoogle ScholarPubMed
Aman, M, De Smedt, G, Derivan, A et al (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry; 159: 1337–46.CrossRefGoogle ScholarPubMed
Armenteros, J, Davies, M (2006) Antipsychotics in early-onset schizophrenia. Systematic review and meta-analysis. European Journal of Child and Adolescent Psychiatry; 15: 141–8.CrossRefGoogle ScholarPubMed
Bachmann, C, Haberhausen, M, Heizel-Gutenbrunner, M et al (2008) Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Therapeutic Drug Monitoring; 30: 108–12.CrossRefGoogle ScholarPubMed
Berger, G, Proffitt, T, McConchie, M et al (2008) Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumurate in 141 patients aged 15 to 25 years. Journal of Clinical Psychiatry; 69: 1702–14.Google Scholar
Bigos, K, Pollock, B, Coley, K et al (2008) Sex, race, and smoking impact olanzapine exposure. Journal of Clinical Pharmacology; 48: 157–65.CrossRefGoogle ScholarPubMed
Blair, J, Scahill, L, State, M et al (2005) Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 73–9.Google ScholarPubMed
Bloch, M, Landeros-Weisenberger, A, Kelmendi, B et al (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry; 11: 622–32.Google ScholarPubMed
Buckley, P, Correll, C (2008) Strategies for dosing and switching for optimal clinical management. Journal of Clinical Psychiatry; 69 (suppl 1): 417.Google ScholarPubMed
Buitelaar, JK, van der Gaag, Cohen-Kettenis P et al (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry; 62: 239–48.Google ScholarPubMed
Campbell, M, Small, A, Green, W et al (1984) Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Archives of General Psychiatry; 41: 650–6.CrossRefGoogle ScholarPubMed
Chavez, B, Chavez-Brown, M, Sopko, M Jr et al (2007) Atypical antipsychotics in children with pervasive developmental disorders. Paediatric Drugs; 9: 249–66.CrossRefGoogle ScholarPubMed
Correll, C, Carlson, H (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry; 45: 771–91.Google ScholarPubMed
Correll, C, Kane, J (2007) One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: a systematic review. Journal of Child and Adolescent Psychopharmacology; 17: 647–55.CrossRefGoogle ScholarPubMed
Correll, C (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. Journal of the American Academy of Child and Adolescent Psychiatry; 47: 920.CrossRefGoogle ScholarPubMed
DelBello, M, Schwiers, M, Rosenberg, H et al (2002) A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry; 41: 1216–23.Google ScholarPubMed
DelBello, M, Kowatch, R, Adler, C et al (2006) A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry; 45: 305–13.Google ScholarPubMed
Doey, T, Handelman, K, Seabrook, J et al (2007) Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental paediatricians for patients aged under 18 years. Canadian Journal of Psychiatry; 52: 363–8.CrossRefGoogle Scholar
Engelhardt, D, Polizos, P, Waizer, J et al (1973) A double blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. Journal of Autism and Childhood Schizophrenia; 3: 128–37.CrossRefGoogle ScholarPubMed
Faretra, G, Dooher, L, Dowling, J (1970) Comparison of haloperidol and fluphenazine in disturbed children. American Journal of Psychiatry; 126: 1670–3.CrossRefGoogle ScholarPubMed
Findling, R, McNamara, N, Branicky, L et al (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry; 39: 509–16.Google ScholarPubMed
Findling, RL, Kusumakar, V, Daneman, D et al (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry; 64: 1362–9.Google ScholarPubMed
Findling, RL, Steiner, H, Weller, EB (2005) Use of antipsychotics in children and adolescents. Journal of Clinical Psychiatry; 66: 2940.Google ScholarPubMed
Findling, R, Frazier, J, Gerbino-Rosen, G et al (2007) Is there a role for clozapine in the treatment of children and adolescents? Journal of the American Academy of Child and Adolescent Psychiatry; 46: 423–8.Google Scholar
Findling, R, Kauffman, R, Sallee, F et al (2008) Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose escalation study. Journal of Clinical Psychopharmacology; 28: 441–6.CrossRefGoogle Scholar
Gaffney, G, Perry, P, Lund, B et al (2002) Risperidone versus clonidine in the treatment of children and adolescents with Tourette's Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry; 41: 330–6.Google ScholarPubMed
Gerbino-Rosen, G, Roofeh, D, Tompkins, D et al (2005) Hematological adverse events in clozapine-treated children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 1024–31.Google ScholarPubMed
Gilbert, D, Batterson, J, Sethuraman, G et al (2004) Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry; 43: 206–14.Google Scholar
Gleason, M, Egger, H, Emslie, G et al (2007) Psychopharmacological treatment for very young children: contexts and guidelines. Journal of the American Academy of Child and Adolescent Psychiatry; 46: 1532–72.Google ScholarPubMed
Gogtay, N, Rapoport, J (2008) Clozapine use in children and adolescents. Expert Opinion on Pharmacotherapy; 9: 459–65.CrossRefGoogle ScholarPubMed
Goldberg, T, Goldman, R, Burdick, K et al (2007) Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Archives of General Psychiatry; 64: 1115–22.CrossRefGoogle ScholarPubMed
Goodyer, I, Dubicka, B, Wilkinson, P et al (2007) Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ; 335: 142.CrossRefGoogle ScholarPubMed
Haas, M, DelBello, MP, Pandina, G et al (2009a) Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disorders; 11: 687700.CrossRefGoogle Scholar
Haas, M, Eerdekens, M, Kushner, S et al (2009b) Efficacy, safety and tolerability of two dosing regimes in adolescent schizophrenia: a double-blind study. British Journal of Psychiatry; 194: 158–64.CrossRefGoogle Scholar
Harrison-Woolrych, M, Garcia-Quiroga, J, Ashton, J et al (2007) Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Safety; 30: 569–79.CrossRefGoogle ScholarPubMed
Hobbs, J, Peterson, D, Moss, A (2006) Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long–OT syndrome. JAMA; 296: 1249–54.CrossRefGoogle ScholarPubMed
Hollander, E, Wasserman, S, Swanson, E et al (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology; 16: 541–8.CrossRefGoogle ScholarPubMed
Jensen, S, Buitelaar, J, Pandina, G et al (2007) Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. European Child and Adolescent Psychiatry; 16: 104–20.CrossRefGoogle ScholarPubMed
Kafantaris, V, Coletti, D, Dicker, R et al (2001) Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. Journal of the American Academy of Child and Adolescent Psychiatry; 40: 1448–56.Google ScholarPubMed
Kapur, S, Zipursky, R, Jones, C et al (2000) Relationship between dopamine D(2) occupancy, clinical response, and side-effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry; 157: 154–20.CrossRefGoogle ScholarPubMed
Kapur, S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry; 160: 1323.CrossRefGoogle Scholar
Kennedy, E, Kumar, A, Datta, SS (2007) Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database of Systematic Reviews; issue 3: CD004027.Google Scholar
Klein, D, Cottingham, E, Sorter, M et al (2006) A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. American Journal of Psychiatry; 163: 2072–9.CrossRefGoogle ScholarPubMed
Kowatch, RA, Fristad, M, Birmaher, B et al (2005) Treatment guidelines for children and adolescents with bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 213–35.Google ScholarPubMed
Kryzhanovskaya, L, Schulz, S, McDougle, C et al (2009) Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry; 48: 6070.CrossRefGoogle Scholar
Kumra, S, Frazier, J, Jacobsen, L et al (1996) Childhood-onset schizophrenia: a double-blind clozapine–haloperidol comparison. Archives of General Psychiatry; 53: 1090–7.CrossRefGoogle ScholarPubMed
Kumra, S, Kranzler, H, Gerbino-Rosen, G et al (2008) Clozapine and ‘high-dose’ olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry; 63: 524–9.CrossRefGoogle ScholarPubMed
Leucht, S, Komossa, K, Rummel-Kluge, C et al (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry; 166: 152–63.CrossRefGoogle ScholarPubMed
Lewis, S, Lieberman, J (2008) CATIE and CUtLASS: can we handle the truth? British Journal of Psychiatry; 192: 161–3.CrossRefGoogle ScholarPubMed
Luby, J, Mrakotsky, C, Stalets, MM et al (2006) Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology; 16: 575–87.CrossRefGoogle ScholarPubMed
March, J, Silva, S, Petrycki, S et al (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA; 292: 807–20.Google ScholarPubMed
McCracken, J, McGough, J, Shah, B et al (2002) Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine; 347: 314–21.CrossRefGoogle ScholarPubMed
McDougle, C, Scahill, L, Aman, MG et al (2005) Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry; 162: 1142–8.CrossRefGoogle Scholar
Medicines and Healthcare products Regulatory Agency (2007) Medicine for children. MHRA (http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesforchildren/index.htm).Google Scholar
Mehler-Wex, C, Romanos, M, Kirhheimer, J et al (2008) Atypical antipsychotics in severe anorexia nervosa in children and adolescents – review and case reports. European Eating Disorders Review; 16: 100–8.CrossRefGoogle ScholarPubMed
Miral, S, Gencer, O, Inal-Emiroglu, F et al (2008) Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child and Adolescent Psychiatry; 17: 18.CrossRefGoogle ScholarPubMed
Morgan, S, Taylor, E (2007) Antipsychotic drugs in children with autism. BMJ; 334: 1069–70.CrossRefGoogle ScholarPubMed
Mukundan, A, Faulkner, G, Cohn, T et al (2007) Antipsychotic switching for people with schizophrenia who have neuroleptics induced weight or metabolic problems (Protocol). Cochrane Database of Systematic Reviews; issue 3: CD006629.Google Scholar
Nagaraj, R, Singhi, P, Malhi, P (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. Journal of Child Neurology; 21: 450–5.CrossRefGoogle ScholarPubMed
National Collaborating Centre for Mental Health (2002) Schizophrenia – Atypical Antipsychotics. National Institute for Health and Clinical Excellence (http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11460).Google Scholar
National Collaborating Centre for Mental Health (2004) Eating Disorders: Core Interventions in the Treatment of Anorexia Nervosa, Bulimia Nervosa, and Related Eating Disorders. National Institute for Health and Clinical Excellence (http://www.nice.org.uk/nicemedia/pdf/cg009niceguidance.pdf).Google Scholar
National Institute for Health and Clinical Excellence (2005) Latest NICE guidance sets new standards for treating depression in children and young people. NICE (http://www.nice.org.uk/guidance/index.jsp?action=download&o=29862).Google Scholar
National Institute for Health and Clinical Excellence (2006) Conduct disorders in children – new guidance to help parents. NICE (http://www.nice.org.uk/newsroom/guidanceinfocus/conduct_disorders_in_children__new_guidance_to_help_parents.jsp).Google Scholar
Olfson, M, Blanco, C, Liu, L et al (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry; 63: 679–85.CrossRefGoogle ScholarPubMed
Pediatric OCD Treatment Study (POTS) Team (2004) Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA; 292: 1969–76.Google Scholar
Pool, D, Bloom, W, Mielke, D et al (1976) A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Current Therapeutic Research, Clinical and Experimental; 19: 99104.Google ScholarPubMed
Realmuto, G, Erickson, W, Yellin, A et al (1984) Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. American Journal of Psychiatry; 141: 440–2.Google ScholarPubMed
Reyes, M, Buitelaar, J, Toren, P et al (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry; 163: 402–10.CrossRefGoogle ScholarPubMed
Sallee, F, Nesbitt, L, Jackson, C et al (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. American Journal of Psychiatry; 154: 1057–62.Google ScholarPubMed
Sallee, F, Kurlan, R, Goetz, C et al (2000) Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry; 39: 292–9.Google ScholarPubMed
Sanford, M, Keating, G (2007) Aripiprazole in adolescents with schizophrenia. Paediatric Drugs; 9: 419–23.Google ScholarPubMed
Scahill, L, Leckman, J, Schultz, R et al (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology; 60: 1130–5.CrossRefGoogle ScholarPubMed
Shaw, P, Sporn, A, Gogtay, N et al (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine–olanzapine comparison. Archives of General Psychiatry; 63: 721–30.CrossRefGoogle ScholarPubMed
Shea, S, Turgay, A, Carroll, A et al (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics; 114: e63441.CrossRefGoogle ScholarPubMed
Shelton, R, Papakostas, G (2008) Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatrica Scandinavica; 117: 253–9.CrossRefGoogle ScholarPubMed
Sikich, L, Hamer, R, Bashford, R et al (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology; 29: 133–45.CrossRefGoogle ScholarPubMed
Sikich, L, Frazier, J, McClellan, J et al (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. American Journal of Psychiatry; 165: 1420–31.CrossRefGoogle ScholarPubMed
Snyder, R, Turgay, A, Aman, M et al (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry; 41: 1026–36.Google ScholarPubMed
Spencer, E, Kafantaris, V, Padron-Gayol, M et al (1992) Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacology Bulletin; 28: 183–6.Google ScholarPubMed
Sporn, A, Vermani, A, Greenstein, D (2007) Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. Journal of the American Academy of Child and Adolescent Psychiatry; 46: 1349–56.Google ScholarPubMed
Spettigue, W, Buchholz, A, Henderson, K et al (2008) Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial. BMC Pediatrics; 8: 4.CrossRefGoogle ScholarPubMed
Sporn, A, Gogtay, N, Ortiz-Aguavo, R et al (2003) Clozapine-induced neutropenia in children: management with lithium carbonate. Journal of Child and Adolescent Psychopharmacology; 13: 401–4.CrossRefGoogle ScholarPubMed
Tohen, M, Kryzhanovskaya, L, Carlson, G et al (2007) Olanzapine versus placebo in the treatment of adolescents with bipolar mania. American Journal of Psychiatry; 164: 1547–56.CrossRefGoogle ScholarPubMed
Troost, P, Lahuis, B, Steenhuis, MP et al (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry; 44: 1137–44.Google ScholarPubMed
Van Bellighen, M, De Troch, C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology; 11: 513.CrossRefGoogle Scholar
Watson, J, Rees, C (2008) Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. Journal of Child Psychology and Psychiatry; 49: 489–98.CrossRefGoogle ScholarPubMed
Wu, RR, Zhao, JP, Guo, XF et al (2008) Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry; 165: 352–8.CrossRefGoogle ScholarPubMed
Xiong, Y (2004) Comparison study of childhood schizophrenia treated with risperidone and chlorpromazine. Guizhou Medical Journal; 28: 697–8.Google Scholar
Yao, H (2003) A study of risperidone in the treatment of child schizophrenia. Journal of Clinical Psychological Medicine; 7468: 801.Google Scholar
Figure 0

TABLE 1 Randomised controlled trials of antipsychotic medication for the treatment of schizophrenia

Figure 1

TABLE 2 Randomised controlled trials of antipsychotic medication for the treatment of bipolar disorder

Figure 2

TABLE 3 Randomised controlled trials of antipsychotic medication for the treatment of pervasive developmental disorder and Tourette syndrome/tics

Figure 3

TABLE 4 Randomised controlled trials of antipsychotic medication for the treatment of disruptive behaviour disorders

Figure 4

TABLE 5 Side-effect profile of second-generation antipsychotics and haloperidol (first-generation antipsychotic)a

Figure 5

MCQ answers

Submit a response

eLetters

No eLetters have been published for this article.
You have Access
10
Cited by